Dry mix formulation for bisphosphonic acids
DCFirst Claim
Patent Images
1. A process for the preparation of a tablet containing an active ingredient selected from:
- 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;
N-methyl-4-amino-1-hydroxybutylidene-1,1-bis-phosphonic acid;
4-(N,N-dimethylamino)-1-hydroxybutylidene-1,1-bisphosphonic acid;
3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid;
3-(N,N-dimethylamino)-1-hydroxypropylidene-1,1-bisphosphonic acid;
1-hydroxy-3-(N-methyl-N-pentylamino)propylidene-1,1-bisphosphonic acid;
1-hydroxy-2- 3-pyridyl!ethylidene-1,1-bisphosphonic acid;
4-(hydroxymethylene-1,1-bisphosphonic acid)piperidine;
or a pharmaceutically acceptable salts thereof;
which process comprises;
forming a mixture by mixing the active ingredient with;
a diluent, selected from;
anhydrous lactose and hydrous fastflow lactose,a dry binder,a disintegrant,and optionally one or more additional ingredients selectedfrom the group consisting of;
compression aids, flavors,flavor enhancers, sweeteners and preservatives;
lubricating the mixture with a lubricant; and
compressing the resultant lubricated mixture into a desiredtablet form.
1 Assignment
Litigations
0 Petitions
Accused Products
Abstract
Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget'"'"'s disease, malignant hypercalcemia, and metastatic bone disease.
45 Citations
17 Claims
-
1. A process for the preparation of a tablet containing an active ingredient selected from:
-
4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid; N-methyl-4-amino-1-hydroxybutylidene-1,1-bis-phosphonic acid; 4-(N,N-dimethylamino)-1-hydroxybutylidene-1,1-bisphosphonic acid; 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid; 3-(N,N-dimethylamino)-1-hydroxypropylidene-1,1-bisphosphonic acid; 1-hydroxy-3-(N-methyl-N-pentylamino)propylidene-1,1-bisphosphonic acid; 1-hydroxy-2- 3-pyridyl!ethylidene-1,1-bisphosphonic acid; 4-(hydroxymethylene-1,1-bisphosphonic acid)piperidine; or a pharmaceutically acceptable salts thereof; which process comprises; forming a mixture by mixing the active ingredient with; a diluent, selected from;
anhydrous lactose and hydrous fastflow lactose, a dry binder, a disintegrant, and optionally one or more additional ingredients selected from the group consisting of;
compression aids, flavors,flavor enhancers, sweeteners and preservatives; lubricating the mixture with a lubricant; and compressing the resultant lubricated mixture into a desired tablet form. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 17)
-
-
9. A pharmaceutical composition comprising by weight, about 0.5 to 40% by weight of an active ingredient selected from the group consisting of:
-
4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid; N-methyl-4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid; 4-(N,N-dimethylamino)-1-hydroxybutylidene-1,1-bisphosphonic acid; 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid; 3-(N,N-dimethylamino)-1-hydroxypropylidene-1,1-bis-phosphonic acid; 1-hydroxy-3-(N-methyl-N-pentylamino)propylidene-1,1-bisphosphonic acid; 1-hydroxy-2- 3-pyridyl!ethylidene-1,1-bisphosphonic acid; and 4-(hydroxymethylene-1,1-bisphosphonic acid)piperidine; or a pharmaceutically acceptable salt thereof; and from about 60 to 99.5% by weight of excipients consisting essentially of;
hydrous fast flow lactose;
microcrystalline cellulose;
croscarmallose sodium; and
magnesium stearate.
-
-
10. A pharmaceutical composition comprising by weight, about 0.5 to 40% by weight of an active ingredient selected from the group consisting of:
-
4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid; N-methyl-4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid; 4-(N,N-dimethylamino)-1-hydroxybutylidene-1,1-bisphosphonic acid; 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid; 3-(N,N-dimethylamino)-1-hydroxypropylidene-1,1-bisphosphonic acid; 1-hydroxy-3-(N-methyl-N-pentylamino)propylidene-1,1-bisphosphonic acid; 1-hydroxy-2- 3-pyridyl!ethylidene-1,1-bisphosphonic acid; and 4-(hydroxymethylene-1,1-bisphosphonic acid)piperidine; or a pharmaceutically acceptable salt thereof; about 10 to 80% by weight of hydrous fast flow lactose; about 5 to 50% by weight of microcrystalline cellulose; about 0.5 to 10% by weight of croscarmallose sodium; and about 0.1 to 5% by weight of magnesium stearate. - View Dependent Claims (11, 12, 13, 14, 15)
-
-
16. A process for the preparation of a table containing as active ingredient a basic nitrogen containing bisphosphonate:
- which process comprises;
forming a mixture by mixing the active ingredient with; a diluent, selected from;
anhydrous lactose or hydrous fast flow lactose,a dry binder, a disintegrant, and optionally one or more additional ingredients selected from the group consisting of;
compression aids, flavors,flavor enhancers, sweeteners and preservatives; lubricating the mixture with a lubricant; and compressing the resultant lubricated mixture into a desired tablet form.
- which process comprises;
Specification